Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

Hiroaki Hagihara, Kazuhiro Nouso, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichiro Nakamura, Kenji Kuwaki, Junichi Toshimori, Hirokazu Miyatake, Hideki Ohnishi, Hidenori Shiraha, Kazuhide Yamamoto

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background We wished to determine whether pegylated interferon (PEG-IFN) therapy after curative treatment of hepatocellular carcinoma (HCC) prevents a recurrence of HCC. Methods Thirty-seven HCC patients with hepatitis C virus (HCV) infection who were treated with PEG-IFN after curative treatment (PEG-IFN group) and 145 controls without IFN therapy (non-IFN group) were enrolled. The overall survival and recurrence-free survival rates were compared between the groups, and the predisposing factors for recurrence and survival were analyzed. The rates were also examined by propensity score (PS) matched analysis that could minimize selection biases. Results The median follow-up period was 3.7 years. The 5-year survival rate in the PEG-IFN group (91%) was significantly higher than that in the non-IFN group (56%; P<0.01). The rate of the second recurrence but not that of the first recurrence of HCC in the sustained virological responder (SVR) group was lower than that in the non-IFN group (P = 0.03). Improvement of survival by PEG-IFN and low rate of second recurrence in the SVR group were also observed in PS matched analysis. Multivariate analysis revealed that PEG-IFN therapy and high serum albumin were good prognostic factors for survival. Although low serum albumin and large and multiple tumors were risk factors for the first recurrence, non-SVR and low serum albumin were risk factors for the second recurrence. Conclusion PEG-IFN-therapy after curative treatment of HCC improved the rate of survival, and SVR was found to be closely correlated with the prevention of recurrence.

Original languageEnglish
Pages (from-to)210-220
Number of pages11
JournalInternational Journal of Clinical Oncology
Volume16
Issue number3
DOIs
Publication statusPublished - Jun 2011

Keywords

  • Hepatitis C virus
  • Hepatocellular carcinoma
  • PEG-IFN
  • Recurrence
  • Survival

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this